L-alaninamide,N-ethyl-N-[1-oxo-4-(4-peperidinyl)butyl]glycyl-L-α-aspartyl-3-cyclohexyl | 169512-56-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: L-alaninamide,N-ethyl-N-[1-oxo-4-(4-peperidinyl)butyl]glycyl-L-α-aspartyl-3-cyclohexyl
• 英文别名: RPR-109891；N-[N-[N-(4-(piperidin-4-yl)butanoyl)-N-ethylglycyl]aspartyl]-L-β-cyclohexyl alanine amide；Klerval；(3S)-4-[[(2S)-1-amino-3-cyclohexyl-1-oxopropan-2-yl]amino]-3-[[2-[ethyl(4-piperidin-4-ylbutanoyl)amino]acetyl]amino]-4-oxobutanoic acid
• CAS: 169512-56-5
• 化学式: C₂₆H₄₅N₅O₆
• 分子量: 523.673
• InChiKey: PWINFPFVCZSLBF-SFTDATJTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  37
• 可旋转键数：
  15
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  171
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• [EN] ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES<br/>[FR] PEPTIDES ET PSEUDOPEPTIDES A GROUPE AZACYCLOALKYLALCANOYLE AYANT DES PROPRIETES ANTITHROMBOTIQUES
  申请人：RHONE-POULENC RORER PHARMACEUTICALS INC.

  公开号：WO1995010295A1

  公开（公告）日：1995-04-20

  (EN) The present invention relates to azacycloalkylalkanoyl peptides and pseudopeptides which inhibit platelet aggregation and thrombus formation thereby being useful in the prevention and treatment of thrombosis associated with disease states such as myocardial infarction, stroke, peripheral arterial disease, and disseminated intravascular coagulation, to methods for the prevention or treatment of thrombosis in a mammal in need of such therapy comprising the administration of a therapeutically effective amount of such compounds, and to pharmaceutical compositions comprising such compounds.(FR) La présente invention concerne des peptides ou pseudopeptides à groupe azacycloalkylalcanoyle qui inhibent l'agrégation plaquettaire et la formation de thrombus, ce qui les rend utiles dans la prévention et le traitement de thromboses que l'on rencontre dans des états pathologiques tels que l'infarctus du myocarde, les accidents cérébrovasculaires, les maladies vasculaires périphériques, et la coagulation intravasculaire disséminée. L'invention concerne également des méthodes de prévention ou de traitement de thromboses chez des mammifères nécessitant une telle thérapie, consistant à d'administrer une dose appropriée de tels composés, ainsi que des compositions pharmaceutiques comprenant de tels composés.

  本发明涉及抑制血小板聚集和血栓形成的氮杂环烷基烷酰肽和假肽，因此可用于预防和治疗与疾病状态相关的血栓形成，如心肌梗死、中风、外周动脉疾病和弥漫性血管内凝血，以及用于治疗需要此类治疗的哺乳动物的预防或治疗血栓形成的方法，包括给予这些化合物的治疗有效量，以及包含这些化合物的制药组合物。
• Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
  申请人：——

  公开号：US20020002268A1

  公开（公告）日：2002-01-03

  The present invention relates to azacycloalkylalkanoyl peptides and pseudopeptides which inhibit platelet aggregation and thrombus formation thereby being useful in the prevention and treatment of thrombosis associated with disease states such as myocardial infarction, stroke, peripheral arterial disease, and disseminated intravascular coagulation, to methods for the prevention or treatment of thrombosis in a mammal in need of such therapy comprising the administration of a therapeutically effective amount of such compounds, and to pharmaceutical compositions comprising such compounds.

  本发明涉及抑制血小板聚集和血栓形成的氮杂环烷基烷酰肽和伪肽，因此在预防和治疗与疾病状态相关的血栓形成，如心肌梗死、中风、外周动脉疾病和弥漫性血管内凝血等方面具有用处，以及用于预防或治疗哺乳动物中需要此类治疗的方法，包括给予这些化合物的治疗有效量，以及包含这些化合物的制药组合物。
• Adenosine as antithrombotic
  申请人：Advanced Gene Technology, Corp.

  公开号：EP1205182A2

  公开（公告）日：2002-05-15

  The present invention discloses a specific binding of adenosine to a platelet membrane receptor protein gpIIb/IIIa, and relates to the novel use of adenosine for inhibiting platelet aggregation and thrombosis. The present invention discloses that adenosine is useful as an antithrombotic.

  本发明公开了腺苷与血小板膜受体蛋白 gpIIb/IIIa 的特异性结合，并涉及腺苷在抑制血小板聚集和血栓形成方面的新用途。本发明公开了腺苷作为抗血栓药物的用途。
• Pharmaceutical composition comprising a compound having anti-xa activity and a platelet aggregation antagonist compound
  申请人：——

  公开号：US20020032214A1

  公开（公告）日：2002-03-14

  The invention is also directed to pharmaceutical composition comprising a compound having anti-Xa activity, a platelet aggregation antagonist compound and a pharmaceutically acceptable carrier. The invention is also directed to a method of treating or preventing a thrombogenic condition associated with a thrombosis related ischemic disorder in a patient comprising administering to said patient pharmaceutically effective amounts of a compound having anti-Xa activity and a platelet aggregation antagonist compound. In addition, this invention is directed to the use of pharmaceutically effective amounts of a compound having anti-Xa activity and a platelet aggregation antagonist compound in the preparation of a medicament for treating or preventing a physiological condition associated with thrombosis related ischemic disorder. Furthermore, this invention is directed to a kit for treating or preventing a physiological condition associated with thrombosis related ischemic disorder, said kit comprising a plurality of separate containers, wherein at least one of said containers contains a compound having anti-Xa activity and at least another of said containers contains a platelet aggregation antagonist compound, and said containers optionally contain a pharmaceutical carrier.

  本发明还涉及药物组合物，其包含具有抗 Xa 活性的化合物、血小板聚集拮抗剂化合物和药学上可接受的载体。本发明还涉及一种治疗或预防与患者血栓形成相关的缺血性疾病的血栓形成条件的方法，包括向所述患者施用药学有效量的具有抗 Xa 活性的化合物和血小板聚集拮抗剂化合物。此外，本发明还涉及将药学有效量的具有抗 Xa 活性的化合物和血小板聚集拮抗剂化合物用于制备治疗或预防与血栓形成相关的缺血性疾病的药物。此外，本发明还涉及一种用于治疗或预防与血栓形成相关的缺血性疾病的生理状况的试剂盒，所述试剂盒包括多个独立的容器，其中至少一个容器含有具有抗 Xa 活性的化合物，至少另一个容器含有血小板聚集拮抗剂化合物，所述容器可选地含有药物载体。
• ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES
  申请人：RHONE-POULENC RORER PHARMACEUTICALS INC.

  公开号：EP0812205B1

  公开（公告）日：2001-03-14